82 CHAPTER 5 S4B: PATIENT CHARACTERISTICS PROBABLY ASSOCIATED WITH A VKA VERSUS A NOAC PRESCRIPTION IN PATIENTS WITH NEW-ONSET ATRIAL FIBRILLATION DIAGNOSED IN 2016. Univariable analyses Variable VKA (n=221) NOAC (n=156) Unadjusted odds ratio (95% CI) Male sex 119 (53.8) 76 (48.7) 1.23 (0.82-1.85) Age in years 78 (72-84.5) 72 (66.25-79) 1.07 (1.04-1.09) Age ≥75 years 144 (65.2) 62 (39.7) 2.84 (1.86-4.33) CHA2DS2-VASc score 4 (2.5-4) 3 (2-4) 1.35 (1.18-1.56) CHA2DS2-VASc score ≥2 201 (91.0) 121 (77.6) 2.91 (1.61-5.27) Heart failure 50 (22.6) 14 (9.0) 2.97 (1.58-5.59) Hypertension 122 (55.2) 82 (52.6) 1.11 (0.74-1.68) Diabetes mellitus 56 (25.3) 23 (14.7) 1.96 (1.15-3.36) CVA or TIA 24 (10.9) 13 (8.3) 1.34 (0.66-2.72) Vascular diseasea 43 (19.5) 16 (10.3) 2.11 (1.14-3.91) Renal impairmentb 63 (28.5) 36 (23.1) 1.33 (0.83-2.13) Dementia 11 (5.0) 0 (0.0) - Asthma or COPD 37 (16.7) 29 (18.6) 0.88 (0.52-1.51) Malignancyc 25 (11.3) 13 (8.3) 1.40 (0.69-2.84) History of bleedingd 58 (26.2) 30 (19.2) 1.49 (0.91-2.46) Multivariable analysese Variable Adjusted odds ratio (95% CI) Age in years 1.06 (1.04-1.09) Diabetes mellitus 1.85 (1.06-3.22) Data are n (%) or median (interquartile range). a Coronary artery disease or peripheral vascular (arterial or venous) disease. b International Classification of Primary Care (ICPC) code U99.01 (renal impairment) or estimated glomerular filtration rate <60 mL/min/1.73 m2. c Five most prevalent malignancies in the Netherlands (apart from skin cancer): breast cancer, prostate cancer, colon cancer, lung cancer, and haematological cancer. d Posttraumatic extradural/subdural/intracerebral haemorrhage, haemoptysis, epistaxis, haematemesis, melaena, haematochezia, haematuria, menorrhagia, postpartum haemorrhage. e Multivariable analyses with stepwise backward elimination (eliminated if p-value ≥0.05) and with age and CHA2DS2-VASc score as continuous instead of dichotomous variables. CI: confidence interval; COPD: chronic obstructive pulmonary disease; CVA: cerebrovascular accident; n: number; NOAC: non-vitamin K antagonist oral anticoagulant; TIA: transient ischemic attack; VKA: vitamin K antagonist.
RkJQdWJsaXNoZXIy MTk4NDMw